Skip to content

A study of the association of biomarkers with cognitive decline in patients with type 2 diabetes

A study of the association of biomarkers with cognitive decline in patients with type 2 diabetes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118326
Enrollment
Unknown
Registered
2026-02-04
Start date
2025-01-01
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Sponsors

The Affiliated Hospita of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: According to the 2020 "Chinese Guidelines for the Prevention and Treatment of Diabetes Mellitus", a diagnosis of diabetes can be made if at least one of the following conditions is met: (1)presence of diabetic symptoms (typical symptoms include polydipsia, polyphagia, polyuria and unexplained weight loss) plus a random venous plasma glucose level of>= 11.1 mmol/L; (2) fasting plasma glucose (FPG) level of >=7.0 mmol/L; (3) oral glucose tolerance test (OGTT), with a 2-hour post-glucose load plasma glucose (2hPG) level of>= 11.1 mmol/L. For those without typical diabetic symptoms, a retest on another day is required for confirmation. Glycated hemoglobin (HbA1c) >= 6.5% can also be used as a diagnostic cut-off point for diabetes. All participants completed the Montreal Cognitive Assessment (MoCA).

Exclusion criteria

Exclusion criteria: (1) Patients with type 1 diabetes, gestational diabetes or other special types of diabetes; (2) Those with abnormal white blood cells, neutrophils and CRP in the blood routine test upon admission or acute infections; (3) Patients with acute complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic coma or other chronic complications; (4) Those with severe mental disorders (such as severe depression) or neurological diseases (transverse myelitis, stroke or brain tumors); (5) Patients with malignant tumors, blood system, autoimmune and related diseases; (6) Those with a history of alcohol abuse, drug addiction, carbon monoxide poisoning, hypothyroidism, vitamin B12 deficiency or folic acid deficiency or other serious chronic diseases; (7) Those with severe cognitive impairment or hearing and vision impairment, which prevent participants from cooperating during the completion of the scale.

Design outcomes

Primary

MeasureTime frame
Biomarkers;the MoCA score;low density lipoprotein;FT3;TyG Index;

Secondary

MeasureTime frame
glycosylated hemoglobin;Fasting blood glucose;Fasting islet function;triglyceride;total cholesterol;high density lipoprotein;

Countries

China

Contacts

Public ContactChangjiang Ying

The Affiliated Hospital of Xuzhou Medical Unviersity

ycj321651@163.com+86 139 1488 8751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026